Preparation, Characterisation and In vivo Evaluation of Bis-demethoxy Curcumin Analogue (BDMCA) Nanoparticles
Abstract
Purpose: To fabricate biodegradable nanoparticle formulation of bis-demethoxy curcumin analogue (BDMCA), a novel curcumin analogue, and evaluate its in vitro and in vivo characteristics. Methods: Nanoparticle formulations were fabricated by a double emulsion solvent evaporation technique using polycaprolactone as the polymer. The nanoparticles were characterised for drug content, particles size, in vitro drug release and the drug-polymer interaction. The in vivo properties of the formulations in male Wistar rats were evaluated from the pharmacokinetics and pharmacodynamics of BDMCA following i.v. administration of the nanoparticles. BDMCA solution was administered i.v. as a reference. Hepatoprotectivity of the formulation was determined in a CCl4-treated rat model. Results: The BDMCA nanoparticles were successfully prepared using double emulsion solvent evaporation technique. The nanoparticle formulations effectively sustained the release of the drug for more than 10 days both in vitro and in vivo. They also offered better pharmacokinetic properties to the drug than that afforded by the free drug itself. Intravenous nanoparticular administration reversed serum liver enzyme levels by 90%, compared to 52 % for repeated i.v. administration of the solution form. Conclusion: BDMCA particle demonstrated good pharmacokinetic and pharmacodynamic properties following i.v. administration.
Keywords: Curcumin analogue; Nanoparticles; pharmacokinetics; Pharmacodynamics; Hepatoprotective activity
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
